menu
    • menu
    [{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Approved","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantheus Holding \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Lantheus Holding \/ Novartis"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"177Lu-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":2.1200000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.1200000000000001,"dosageForm":"","sponsorNew":"Lantheus Holding \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Lantheus Holding"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"177Lu-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Lantheus Holding"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dotatate Lutenium Lu-177","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Not Applicable"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Perspective Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"212Pb-VMT-alpha-NET","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lantheus Holding","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Perspective Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Lantheus Holding \/ Perspective Therapeutics"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"[Lu-177]-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantheus Holding \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Point Biopharma"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"[68Ga]-Trivehexin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lantheus Holding","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lantheus Holding \/ Lantheus Holding","highestDevelopmentStatusID":"14","companyTruncated":"Lantheus Holding \/ Lantheus Holding"}]

    Find Clinical Drug Pipeline Developments & Deals by Lantheus Holding

    Menu

    Lantheus Holding

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lantheus Holding

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : [68Ga]-Trivehexin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Radiopharm Theranostics

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Radiopharm Receives Strategic Investment for up to A$18 million

                            Details : The company will use the net proceeds of Lantheus’ investment for drug advancement RAD301 ([68Ga]-Trivehexin), which is being evaluated for treating pancreatic neoplasms.

                            Brand Name : RAD301

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 19, 2024

                            Lead Product(s) : [68Ga]-Trivehexin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Radiopharm Theranostics

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lantheus Holding

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotatate Lutenium Lu-177

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lantheus Announces Acceptance of ANDA for Generic LUTATHERA®

                            Details : Lutathera-Generic (Lutetium Lu 177 Dotatate) is a radiolabeled somatostatin analog for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

                            Brand Name : Lutathera-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 11, 2024

                            Lead Product(s) : Dotatate Lutenium Lu-177

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lantheus Holding

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212Pb-VMT-alpha-NET

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Perspective Therapeutics

                            Deal Size : $61.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lantheus Expands Radiopharmaceutical Oncology Pipeline through Strategic Agreements

                            Details : Under the agreement, Lantheus obtains an exclusive license for Perspective’s Pb212-VMT-⍺-NET, a clinical-stage alpha therapy developed for the treatment of neuroendocrine tumors.

                            Brand Name : 212Pb-VMT-alpha-NET

                            Molecule Type : Small molecule

                            Upfront Cash : $28.0 million

                            January 09, 2024

                            Lead Product(s) : 212Pb-VMT-alpha-NET

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Perspective Therapeutics

                            Deal Size : $61.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lantheus Holding

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : [Lu-177]-PNT2002

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Point Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castrat...

                            Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy under phase 3 clinical development for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

                            Brand Name : [Lu-177]-PSMA-I&T

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            December 18, 2023

                            Lead Product(s) : [Lu-177]-PNT2002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Point Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lantheus Holding

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu-PNT2002

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Point Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of...

                            Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

                            Brand Name : PNT2002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 24, 2023

                            Lead Product(s) : 177Lu-PNT2002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Point Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lantheus Holding

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu-PNT2002

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Point Biopharma

                            Deal Size : $2,115.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commerc...

                            Details : Lu-177-PSMA-I&T (Lu-177-PNT2002) is a PSMA-Targeted therapy for mCRPC. PSMA is overexpressed in the vast majority of prostate cancers, but very limited to normal tissues. PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisot...

                            Brand Name : 177Lu-PSMA-I&T

                            Molecule Type : Large molecule

                            Upfront Cash : $260.0 million

                            November 14, 2022

                            Lead Product(s) : 177Lu-PNT2002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Point Biopharma

                            Deal Size : $2,115.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lantheus Holding

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development

                            Details : As part of the agreement with Novartis, Lantheus will provide PYLARIFY for the selection of patients with prostate cancer and Novartis will provide all PYLARIFY related clinical imaging data to Lantheus.

                            Brand Name : Pluvicto

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 29, 2022

                            Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth